CN116426391A - Aureobasidium pullulans Aureobasidium pullulans P1 and application thereof - Google Patents
Aureobasidium pullulans Aureobasidium pullulans P1 and application thereof Download PDFInfo
- Publication number
- CN116426391A CN116426391A CN202310309581.6A CN202310309581A CN116426391A CN 116426391 A CN116426391 A CN 116426391A CN 202310309581 A CN202310309581 A CN 202310309581A CN 116426391 A CN116426391 A CN 116426391A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- aureobasidium pullulans
- rare
- fermentation
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000223678 Aureobasidium pullulans Species 0.000 title claims abstract description 27
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims abstract description 21
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims abstract description 21
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000000855 fermentation Methods 0.000 claims abstract description 16
- 230000004151 fermentation Effects 0.000 claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 claims abstract description 11
- 229930182494 ginsenoside Natural products 0.000 claims description 30
- 229940089161 ginsenoside Drugs 0.000 claims description 24
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 3
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 15
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 abstract description 9
- 101000874334 Dalbergia nigrescens Isoflavonoid 7-O-beta-apiosyl-glucoside beta-glycosidase Proteins 0.000 abstract description 4
- 101000757733 Enterococcus faecalis (strain ATCC 700802 / V583) Autolysin Proteins 0.000 abstract description 4
- 101000757734 Mycolicibacterium phlei 38 kDa autolysin Proteins 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 229930182490 saponin Natural products 0.000 abstract description 4
- 150000007949 saponins Chemical class 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000012535 impurity Substances 0.000 abstract description 2
- 238000011027 product recovery Methods 0.000 abstract description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 2
- 239000012071 phase Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 3
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 239000012084 conversion product Substances 0.000 description 3
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 3
- 229940093496 esculin Drugs 0.000 description 3
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 triterpene glycoside compound Chemical class 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 1
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/20—Preparation of steroids containing heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses Aureobasidium pullulans P1 and application thereof in rare saponin conversion, and belongs to the technical field of microorganisms and biological medicines. The strain deposit number is: cgmccno.23227. The Aureobasidium pullulans P1 can be used for preparing rare ginsenoside Rg3 and CK by converting ginsenoside Rb1 by beta-glycosidase through fermentation, the target products are various and definite, other impurities have small interference, the products are easy to generate, the conversion specificity is high, the efficiency is high, the product recovery rate is over 60 percent, and the method has obvious advantages in the process of producing Rg3 and CK by mass fermentation.
Description
Technical Field
The invention relates to the technical field of microorganisms and biological medicines, in particular to aureobasidium pullulans Aureobasidium pullulans P1 and application thereof in preparing rare ginsenoside by converting ginsenoside Rb 1.
Background
Ginsenoside is triterpene glycoside compound, and is a main medicinal active ingredient of Ginseng radix, and is classified into main ginsenoside (Major ginsenoside, such as Rb1, rb2, rc, rd, re, rg1, etc. accounting for more than 80% of total saponins) and Rare ginsenoside (Rare ginsenosides, such as Rg3, rh1, rh2, F1, F2, CK, C-O, CY, C-Mc), etc. according to its content in plant. The rare ginsenoside refers to the saponin with extremely low or no content in the ginseng, but the pharmacological activity of the rare ginsenoside is superior to that of the high-content ginsenoside, for example, the rare ginsenoside Rg3 has various pharmacological activities of resisting tumor, preventing and treating cardiovascular and cerebrovascular diseases and coronary heart disease, inhibiting cancer cell metastasis, protecting liver, protecting nerves, improving immunity and the like; the rare ginsenoside CK has good anti-cell mutation, tumor cell metastasis inhibiting, tumor cell apoptosis inducing, tumor cell drug resistance reversing, antiallergic and anti-inflammatory activities.
Although ginsenoside Rg3 and CK have high medicinal value, they are very rare in nature, and are difficult to separate from ginseng and other plants by a traditional method, which causes great limitation on the production of rare ginsenosides. Currently, the methods for preparing rare ginsenoside are mainly a direct acid hydrolysis method and a microorganism/enzyme conversion method. Direct acid hydrolysis is generally poor in selectivity, low in yield, not easy to purify, and easy to cause environmental pollution. The microorganism/enzyme conversion method has the advantages of high regioselectivity, stereoselectivity, high group selectivity, good targeting property, high yield, few byproducts, no pollution, easy industrial production and the like, can complete some reactions which are difficult to carry out by chemical methods, and obtains rare ginsenoside such as Rg3 and CK which are difficult to obtain by chemical methods, thus being considered as the most potential method for producing the rare ginsenoside.
The ginsenoside is used as a substrate to be converted into specific rare ginsenoside, so that the resource utilization rate can be improved, the extraction cost of the ginsenoside raw material can be reduced, but the specificity of various enzymes to the substrate is different, and the types of degraded glycosidic bonds are different. The strain capable of converting ginsenoside Rb1 and simultaneously generating Rg3 and CK is few, the recovery rate of the product is low, and the practical application of large-scale production of Rg3 and CK cannot be satisfied. Therefore, the search for strains capable of producing glycoside hydrolase with high efficiency and specificity for degrading ginsenoside Rb1 to produce ginsenoside Rg3 and CK by fermentation becomes a key point of research.
Disclosure of Invention
In view of this, the invention provides a Aureobasidium pullulans Aureobasidium pullulans P1 and application thereof.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
aureobasidium pullulans (Aureobasidium pullulan) P1 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No.23227 at the 9 th month 10 year 2021, and is classified and named Aureobasidium pullulans Aureobasidium pullulans by the national institute of microbiology, national institute of sciences, north Chen West Lu No.1, the Korean region of Beijing.
Another object of the present invention is to provide an application of the aureobasidium pullulans P1 in preparing rare ginsenoside by converting ginsenoside Rb 1.
Preferably, the rare ginsenoside is rare ginsenoside Rg3 and rare ginsenoside CK.
Preferably, the conversion of ginsenoside Rb1 to rare ginsenoside is achieved by fermenting Aureobasidium pullulans P1 to produce beta-glucosidase.
Preferably, the conversion path of the ginsenoside Rb1 into rare ginsenoside is Rb 1-Rd-Rg 3; the conversion route of ginsenoside Rb1 into rare ginsenoside CK is Rb 1-Rd-F2-CK.
Compared with the prior art, the invention discloses and provides the aureobasidium pullulans Aureobasidium pullulans P strain which can convert main ginsenoside Rb1 into commercial rare ginsenoside Rg3 and CK with high added value, and has the advantages of various and clear target products, small interference of other impurities, easy generation of the products and obvious advantages in the process of producing Rg3 and CK by mass fermentation. In addition, the specificity of transformation is strong, the efficiency of transforming Rb1 into rare ginsenoside is high, and the product recovery rate is more than 60%.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are required to be used in the embodiments or the description of the prior art will be briefly described below, and it is obvious that the drawings in the following description are only embodiments of the present invention, and that other drawings can be obtained according to the provided drawings without inventive effort for a person skilled in the art.
FIG. 1 shows colony morphology characteristics of Aureobasidium pullulans P1 strain;
FIG. 2 is a phylogenetic tree construction of Aureobasidium pullulans strain;
FIG. 3 is a HPLC detection chart of ginsenoside Rb1 and conversion products in fermentation broth before and after fermentation conversion of Aureobasidium pullulans Aureobasidium pullulans P strain;
FIG. 4 is a conversion pathway of the main ginsenoside Rb1 to rare ginsenosides;
FIG. 5 is a HPLC detection chart of ginsenoside before and after preparing beta-glycosidase by fermenting Aureobasidium pullulans Aureobasidium pullulans P1 and using the glycosidase to convert main ginsenoside Rb 1.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
In order to further understand the present invention, the following details are set forth in the examples, wherein the reagents involved in the examples may be purchased commercially, unless otherwise specified, and the methods not mentioned are conventional experimental methods, and are not described in detail herein.
Example 1: identification of Aureobasidium pullulans Aureobasidium pullulans P1
1. Isolation and culture of strains
The strain is derived from plant seven endophytic fungi, and the specific culture method comprises the steps of cutting root tissues of wild seven of the Qinling mountain into 1 cm, sequentially disinfecting 1min with 75% ethanol, 2min with 2.5% sodium hypochlorite, and 1min with 75% ethanol, washing 3-5 times with sterile water, placing into a culture dish which is sterilized in advance, inserting tissue blocks into a PDA culture medium flat plate containing 100U/mL of acarmiacin sulfate with sterile forceps, and then inversely culturing for 5-7 d in a constant temperature incubator at 28 ℃ until mycelia grow out.
2. Screening and identification of strains
Inoculating mycelium grown on a PDA plate to an R2A culture medium containing esculin, and culturing in an inverted manner for 5-7 d in a constant temperature incubator at 28 ℃, wherein the esculin-R2A agar culture medium comprises the following components: 1g/L esculin, 0.5g/L ferric citrate, 15.2g/L R A commercial medium. The culture medium was sterilized at 121℃for 20min.
If the strain is able to produce a beta-glucosidase to hydrolyze esculin, a red halo will be produced around the growth of the strain. After the detection, a strain capable of producing beta-glycosidase is obtained by screening, and is named as a P1 strain, and colony characteristics are shown in figure 1.
Sequencing the strain by the Dahua biological technology Co., ltd, wherein the ITS sequence of the strain is shown as SEQ ID NO. 1. Sequencing results Blast similarity analysis was performed in NCBI nucleic acid database, and Blast sequence alignment and treeing analysis (see FIG. 2) were performed to determine that they were Aureobasidium pullulans.
Example 2: identification of fermentation Performance of Aureobasidium pullulans Aureobasidium pullulans P1 on Rb1
Culturing Aureobasidium pullulans Aureobasidium pullulans P1 strainCulturing in PDA culture medium at 28deg.C for 5d, and inoculating the bacterial block into liquid culture solution comprising the following components: 20g/L glucose, 10g/L yeast powder, 0.5g/L NaNO 3 ,1g/L KH 2 PO 4 ,2g/LNa 2 HPO 4 ,0.2g/L FeSO 4 ,0.1g/L ZnSO 4 ,0.2g/L CuSO 4 ,1g/L CaCl 2 ,0.5g/L MgSO 4 ·7H 2 O. The initial pH was 6.5, and the culture was carried out at a temperature of 28℃and a rotation speed of 180rpm for 72 hours.
Dissolving ginsenoside Rb1 with 2% methanol aqueous solution to obtain ginsenoside Rb1 mother solution with concentration of 200mg/L, filtering, sterilizing, adding into the fermentation broth of Aureobasidium pullulans Aureobasidium pullulans P, fermenting for 72 hr, and culturing for 6 hr; 2mL of supernatant is taken and added with n-butanol with the volume of 2 times for extraction, then the n-butanol phase at the upper layer is removed to a new culture dish, and the culture dish is placed in a fume hood for volatilizing until the weight is constant, so as to obtain a dry substance.
The dried material was dissolved in methanol and then subjected to liquid phase HPLC detection under the following chromatographic conditions: the chromatographic column adopts YMC-Pack ODS-AQ with the specification of 250mm multiplied by 4.6mm and 5 μm; the mobile phase adopts A phase-B phase, the A phase is water, the B phase is 23wt% acetonitrile, and the gradient elution mode is as follows: 0 to 12min, 77 to 48 weight percent of A is adopted; for 12-35 min, 48-25wt% of A is adopted; 35-36 min, 25wt% of A is adopted; 36-42 min, 25-77 wt% of A is adopted. The volume flow rate in the gradient elution process is 1mL/min, the column temperature is 30 ℃, and the sample injection amount is 10 mu L. All samples were subjected to absorbance detection at 203 nm.
HPLC detection is carried out on the strain fermentation Rb1 product, and the strain fermentation Rb1 product is compared with the HPLC spectrogram and data of the standard strain ginsenoside (see figure 3), in the conversion product, the content of Rb1 is reduced, the ginsenoside Rd, F2, rg3 and CK are generated, and the strain can convert the ginsenoside Rb1 into rare saponins Rg3 and CK, and the conversion paths (see figure 4) are Rb1, rd, rg3 and Rb1, rd, F2 and CK respectively.
Example 3: identification of Rb1 fermentation performance of beta-glycosidase prepared by fermentation of Aureobasidium pullulans Aureobasidium pullulans P1
Aureobasidium pullulans AureobasidiThe um pullulans P1 strain is cultivated in PDA culture medium, cultivated for 5d at 28 ℃, then the bacterial block is inoculated into liquid culture liquid, and the components of the liquid culture liquid are as follows: 20g/L glucose, 10g/L yeast powder, 0.5g/L NaNO 3 ,1g/L KH 2 PO 4 ,2g/L Na 2 HPO 4 ,0.2g/L FeSO 4 ,0.1g/L ZnSO 4 ,0.2g/L CuSO 4 ,1g/L CaCl 2 ,0.5g/L MgSO 4 ·7H 2 O. The initial pH was 6.5, and the culture was carried out at a temperature of 28℃and a rotation speed of 180rpm for 96 hours.
Centrifuging the fermentation liquor at 8000 rpm/mm after the culture is finished to remove thalli, adding 70% ammonium sulfate into supernatant to carry out salting out, standing overnight at 4 ℃ and centrifuging to obtain crude protein, dissolving the crude protein in water, desalting by a dialysis bag, and freeze-drying the desalted enzyme solution to obtain an enzyme sample; respectively dissolving enzyme sample and ginsenoside Rb1 with phosphate buffer with pH of 5.0 to obtain 200mg/L enzyme solution and 200mg/L ginsenoside Rb1 solution, mixing the enzyme solution and ginsenoside Rb1 solution uniformly in equal volume, and reacting in a water bath at 55deg.C for 1 hr. After the reaction, the reaction solution is extracted by 2 times of n-butanol, the n-butanol phase at the upper layer is removed to a new culture dish, and then the culture dish is placed in a fume hood for volatilizing until the weight is constant, so as to obtain a dry product.
The dried material was dissolved in methanol and then subjected to liquid phase HPLC detection under the following chromatographic conditions: the chromatographic column adopts YMC-Pack ODS-AQ with the specification of 250mm multiplied by 4.6mm and 5 μm; the mobile phase adopts A phase-B phase, the A phase is water, the B phase is 23wt% acetonitrile, and the gradient elution mode is as follows: 0 to 12min, 77 to 48 weight percent of A is adopted; for 12-35 min, 48-25wt% of A is adopted; 35-36 min, 25wt% of A is adopted; 36-42 min, 25-77 wt% of A is adopted. The volume flow rate in the gradient elution process is 1mL/min, the column temperature is 30 ℃, and the sample injection amount is 10 mu L. All samples were subjected to absorbance detection at 203 nm.
HPLC detection is carried out on the strain fermentation Rb1 product, and the strain fermentation Rb1 product is compared with the HPLC spectrogram and data of the ginsenoside in the standard strain (see figure 5), in the conversion product, rb1 is completely degraded, only rare ginsenoside Rg3 and CK are detected, and the recovery rate of the rare ginsenoside Rg3 and CK is obtained by peak area calculation and exceeds 60 percent.
In the present specification, each embodiment is described in a progressive manner, and each embodiment is mainly described in a different point from other embodiments, and identical and similar parts between the embodiments are all enough to refer to each other. For the device disclosed in the embodiment, since it corresponds to the method disclosed in the embodiment, the description is relatively simple, and the relevant points refer to the description of the method section.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (6)
1. Aureobasidium pullulans (Aureobasidium pullulans) P1, characterized by the preservation number: cgmccno.23227.
2. The use of a strain of aureobasidium pullulans P1 as claimed in claim 1 for preparing rare ginsenoside by converting ginsenoside Rb 1.
3. The use according to claim 2, wherein the rare ginsenosides are rare ginsenosides Rg3 and rare ginsenosides CK.
4. The use according to claim 2, wherein the transformation is effected by fermentation of aureobasidium pullulans P1 to produce β -glucosidase.
5. The use according to claim 2, wherein the conversion pathway of ginsenoside Rb1 to rare ginsenoside is rb1→rd→rg3.
6. The use according to claim 2, wherein the conversion pathway of ginsenoside Rb1 to rare ginsenoside CK is rb1→rd→f2→ck.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310309581.6A CN116426391B (en) | 2023-03-28 | 2023-03-28 | Aureobasidium pullulans Aureobasidium pullulans P1 and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310309581.6A CN116426391B (en) | 2023-03-28 | 2023-03-28 | Aureobasidium pullulans Aureobasidium pullulans P1 and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116426391A true CN116426391A (en) | 2023-07-14 |
CN116426391B CN116426391B (en) | 2024-02-23 |
Family
ID=87086498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310309581.6A Active CN116426391B (en) | 2023-03-28 | 2023-03-28 | Aureobasidium pullulans Aureobasidium pullulans P1 and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116426391B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116836818A (en) * | 2023-07-28 | 2023-10-03 | 陕西省微生物研究所 | Penicillium strain F8816 and application thereof |
CN117089465A (en) * | 2023-08-22 | 2023-11-21 | 陕西省微生物研究所 | Aspergillus wart and application thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150102360A (en) * | 2014-02-28 | 2015-09-07 | 주식회사 코리아나화장품 | Cosmetic composition containing an ginsenoside Rg3 reinforced extract of fermentative Ginseng flower(Panax ginseng C. A. Meyer) by Aureobasidium pullulans |
CN105296587A (en) * | 2015-11-18 | 2016-02-03 | 湖南工程学院 | Method for preparing rare ginsenoside CK from transformed ginsenoside Rb1 and use thereof |
CN105420127A (en) * | 2016-01-18 | 2016-03-23 | 陕西省微生物研究所 | High-yielding strain of high molecular weight pullulan and method for producing high molecular weight pullulan by utilizing high-yielding strain |
CN108888565A (en) * | 2018-09-30 | 2018-11-27 | 长春中医药大学 | A kind of anti-oxidation function toner and preparation method thereof adding ginseng lipoid plastid |
KR101952951B1 (en) * | 2018-11-18 | 2019-02-28 | 주식회사 아리바이오 | Production method of black yeast culture liquid containing compound k, functional cosmetic and compound containing compound k |
US20220184106A1 (en) * | 2019-03-21 | 2022-06-16 | Hewei Li | Freeze-dried formulation, preparation method and application thereof |
CN115334898A (en) * | 2020-05-21 | 2022-11-11 | 汉坰妊 | Environment-friendly growth auxiliary and preparation method thereof |
CN115531272A (en) * | 2022-04-18 | 2022-12-30 | 广东芭薇生物科技股份有限公司 | Antioxidant composition derived from alpine plants and preparation method and application thereof |
-
2023
- 2023-03-28 CN CN202310309581.6A patent/CN116426391B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150102360A (en) * | 2014-02-28 | 2015-09-07 | 주식회사 코리아나화장품 | Cosmetic composition containing an ginsenoside Rg3 reinforced extract of fermentative Ginseng flower(Panax ginseng C. A. Meyer) by Aureobasidium pullulans |
CN105296587A (en) * | 2015-11-18 | 2016-02-03 | 湖南工程学院 | Method for preparing rare ginsenoside CK from transformed ginsenoside Rb1 and use thereof |
CN105420127A (en) * | 2016-01-18 | 2016-03-23 | 陕西省微生物研究所 | High-yielding strain of high molecular weight pullulan and method for producing high molecular weight pullulan by utilizing high-yielding strain |
CN108888565A (en) * | 2018-09-30 | 2018-11-27 | 长春中医药大学 | A kind of anti-oxidation function toner and preparation method thereof adding ginseng lipoid plastid |
KR101952951B1 (en) * | 2018-11-18 | 2019-02-28 | 주식회사 아리바이오 | Production method of black yeast culture liquid containing compound k, functional cosmetic and compound containing compound k |
US20220184106A1 (en) * | 2019-03-21 | 2022-06-16 | Hewei Li | Freeze-dried formulation, preparation method and application thereof |
CN115334898A (en) * | 2020-05-21 | 2022-11-11 | 汉坰妊 | Environment-friendly growth auxiliary and preparation method thereof |
CN115531272A (en) * | 2022-04-18 | 2022-12-30 | 广东芭薇生物科技股份有限公司 | Antioxidant composition derived from alpine plants and preparation method and application thereof |
Non-Patent Citations (4)
Title |
---|
CHAO AN等: "Efficient production of pullulan by Aureobasidium pullulans grown on mixtures of potato starch hydrolysate and sucrose", BRAZ J MICROBIOL, vol. 48, no. 1, pages 180 - 185, XP055651880, DOI: 10.1016/j.bjm.2016.11.001 * |
常军;周斌;胡娜;: "黑曲霉葡萄糖苷酶的分离纯化及酶学性质研究", 安徽农业科学, no. 19, pages 11374 - 11376 * |
常帆;薛文娇;安超;马赛箭;: "出芽短梗霉及其生物产品研究进展", 保鲜与加工, no. 04, pages 11 - 16 * |
李冰;相苒;王玉华;姚曼;张敏;张予心;宋秋梅;杨雪娇;: "出芽短梗霉发酵生产茁霉多糖工艺优化研究", 食品科技, no. 09, pages 48 - 56 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116836818A (en) * | 2023-07-28 | 2023-10-03 | 陕西省微生物研究所 | Penicillium strain F8816 and application thereof |
CN116836818B (en) * | 2023-07-28 | 2024-03-22 | 陕西省微生物研究所 | Penicillium strain F8816 and application thereof |
CN117089465A (en) * | 2023-08-22 | 2023-11-21 | 陕西省微生物研究所 | Aspergillus wart and application thereof |
CN117089465B (en) * | 2023-08-22 | 2024-05-03 | 陕西省微生物研究所 | Aspergillus wart and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN116426391B (en) | 2024-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116426391B (en) | Aureobasidium pullulans Aureobasidium pullulans P1 and application thereof | |
CN1479787B (en) | Ginsenoside glycosidase of hydrolyze ginseng saponin glycosyl and its application | |
KR101671435B1 (en) | Strain having ginsenoside bioconversion activity and manufacturing method of fermented red ginseng extract using the same | |
CN103146592B (en) | Microzyme converting ginsenoside Rb1 to generate Rd and application thereof | |
CN116836818B (en) | Penicillium strain F8816 and application thereof | |
CN111617120B (en) | Preparation method of ginseng cordyceps sinensis fermentation extract | |
CN104357332A (en) | Aspergillus niger JH-2 and application to biotransformation and synthesis of asiatic acid | |
CN103937691A (en) | Aspergillus oryzae strain capable of producing beta-fructofuranosidase, as well as culture method and application thereof | |
CN112575050A (en) | Method for preparing diosgenin by biological conversion | |
CN116790386A (en) | Penicillium sp.YMS6 strain and application thereof | |
CN113717860B (en) | Application of Huang Lanzhuang bacteria in conversion of total saponins of Notoginseng radix into small-polarity ginsenoside | |
CN102433289B (en) | Strain for producing citrulline and method for biologically synthesizing citrulline with same | |
CN106591142B (en) | Xylariales endophyte and application thereof | |
CN105199966B (en) | A kind of conversion ginsenoside Rb1 produces aspergillus and the application of Rd | |
CN117089465B (en) | Aspergillus wart and application thereof | |
CN109735473B (en) | Method for preparing water-soluble curcumin by fermentation | |
KR102084980B1 (en) | Aspergillus oryzae GBE174 and method for preparing fermentated extract of ginseng berry using the same | |
CN111485012B (en) | Method for preparing glycyrrhetinic acid monoglucuronide by liquorice fermentation | |
CN103865804B (en) | Beta-glucosidase Producing Strain and the application in resveratrol is prepared in conversion thereof | |
CN107988109B (en) | flavobacterium mutant strain and application thereof | |
CN110156807A (en) | The purposes of aspergillus flavus OUCMDZ-2205 secondary metabolite | |
CN117736884A (en) | Aspergillus ochraceus F8509 and application thereof | |
CN111979139B (en) | Bacillus belgii G9y and application thereof in ginsenoside biotransformation | |
CN117247842A (en) | Metascus fungus X-Z-5 for converting ginsenoside Rb1 and application thereof | |
CN111440735B (en) | Baicalensis endophyte for producing cellulase and application of enzyme produced by same in extraction of baicalin from Baicalensis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |